Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2010 1
2011 2
2012 2
2013 2
2014 5
2015 3
2016 4
2017 7
2018 3
2020 1
2021 3
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group. Finkel RS, et al. N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752. N Engl J Med. 2017. PMID: 29091570 Free article. Clinical Trial.
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group. Mercuri E, et al. N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504. N Engl J Med. 2018. PMID: 29443664 Free article. Clinical Trial.
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J, Bouras E, Constantinescu A, Burrows K, Bull CJ, Vincent EE, Martin RM, Dimopoulou O, Lewis SJ, Moreno V, Vujkovic M, Chang KM, Voight BF, Tsao PS, Gunter MJ, Hampe J, Pellatt AJ, Pharoah PDP, Schoen RE, Gallinger S, Jenkins MA, Pai RK; PRACTICAL consortium; VA Million Veteran Program; Gill D, Tsilidis KK. Yarmolinsky J, et al. Among authors: constantinescu a. Diabetologia. 2023 Aug;66(8):1481-1500. doi: 10.1007/s00125-023-05925-4. Epub 2023 May 12. Diabetologia. 2023. PMID: 37171501 Free PMC article.
A Cross-Sectional Study of Nemaline Myopathy.
Amburgey K, Acker M, Saeed S, Amin R, Beggs AH, Bönnemann CG, Brudno M, Constantinescu A, Dastgir J, Diallo M, Genetti CA, Glueck M, Hewson S, Hum C, Jain MS, Lawlor MW, Meyer OH, Nelson L, Sultanum N, Syed F, Tran T, Wang CH, Dowling JJ. Amburgey K, et al. Among authors: constantinescu a. Neurology. 2021 Mar 9;96(10):e1425-e1436. doi: 10.1212/WNL.0000000000011458. Epub 2021 Jan 4. Neurology. 2021. PMID: 33397769 Free PMC article.
ptARgenOM-A Flexible Vector For CRISPR/CAS9 Nonviral Delivery.
Radoua A, Pernon B, Pernet N, Jean C, Elmallah M, Guerrache A, Constantinescu AA, Hadj Hamou S, Devy J, Micheau O. Radoua A, et al. Among authors: constantinescu aa. Small Methods. 2023 Jul;7(7):e2300069. doi: 10.1002/smtd.202300069. Epub 2023 May 8. Small Methods. 2023. PMID: 37156748
The promise of EPC-based therapies on vascular dysfunction in diabetes.
Georgescu A, Alexandru N, Constantinescu A, Titorencu I, Popov D. Georgescu A, et al. Among authors: constantinescu a. Eur J Pharmacol. 2011 Nov 1;669(1-3):1-6. doi: 10.1016/j.ejphar.2011.07.035. Epub 2011 Aug 5. Eur J Pharmacol. 2011. PMID: 21839073 Review.
Profiling oocytes with neural networks from images and mechanical data.
Lamont S, Fropier J, Abadie J, Piat E, Constantinescu A, Roux C, Vernerey F. Lamont S, et al. Among authors: constantinescu a. J Mech Behav Biomed Mater. 2023 Feb;138:105640. doi: 10.1016/j.jmbbm.2022.105640. Epub 2022 Dec 21. J Mech Behav Biomed Mater. 2023. PMID: 36566663
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Montfort A, et al. Among authors: constantinescu aa. Cancer Immunol Res. 2021 May;9(5):568-582. doi: 10.1158/2326-6066.CIR-20-0342. Epub 2021 Mar 16. Cancer Immunol Res. 2021. PMID: 33727246 Free PMC article.
38 results